Nicola Micale

University of Messina, Italy
Lecture Title: 
"Drug design and biological activity of compounds targeting human and/or pathogenic proteases"

Prof. Nicola Micale, received the PhD in Pharmaceutical Sciences at the University of Messina in 2000. In the next two years he was holder of a postdoc fellowship. From 2002 to 2006, he got a research contract within the project: "New Agents for the Treatment of Pathologies Neurodegenerative". In 2003-2004, he joined Prof. Dr. A. P. Kozikowski, first at the Department of Neurology, Georgetown University Medical Center, Washington DC, then at the Department of Medicinal Chemistry & Pharmacognosy, Illinois University, Chicago, where within the "Drug Discovery Program" he undertook a study on peptidomimetic cysteine protease inhibitors. In 2006 he received the “Farmindustria Prize” for the quality of his researches in the Medicinal Chemistry field. In 2006-2007 he was “Guest Professor” at the Department of Pharmaceutical Sciences, University of Copenhagen. From 2008 to 2019 he worked periodically and constantly as “Visiting Scientist” at the Institut für Pharmazie und Lebensmittelchemie, Bayerische Julius- Maximilians-Universität of Würzburg and at the Institut für Pharmazie und Biochemie, Johannes Gutenberg Universität of Mainz within a steady research collaboration with Prof. Dr. Tanja Schirmeister. In 2013-2014 he worked for six months at the National Physical Laboratory of London within the “Biotechnology Group” of Dr. Max Ryadnov. He worked also as “Visiting Scientist” (2017) at the KU Leuven (BE), Department of Pharmaceutical and Pharmacological Sciences, Division of “Molecular Virology and Gene Therapy”. From 2018 he is Associate Professor at the University of Messina and on July 10th, 2020 he has been appointed as Full Professor by the National Academic Committee. He is co-author of 80 publications and 54 communications at national and international meetings. His current research is mainly focused on biopolymers for the development of drug delivery systems for active and/or passive targeting of bioactive molecules, design and synthesis of heterocyclic/peptidic compounds targeting human and/or pathogenic proteases, and biological activity of metal complexes.